Citius Oncology (CTOR) Enterprise Value (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Enterprise Value of -$2.6 million for Q1 2026, down 2350466.07% year-over-year from N/an in Q1 2025, and up 63.91% quarter-over-quarter from -$7.3 million in Q4 2025.
Citius Oncology (CTOR) Enterprise Value (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Enterprise Value for 5 consecutive years, with -$2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 2350466.07% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at -$2.6 million (down 2350466.07% YoY), while the FY2025 annual figure was -$3.9 million, down 3504282.14% from the prior year.
- Enterprise Value improved to -$2.6 million in Q1 2026 per CTOR's latest filing, from -$7.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$112.0 in Q3 2024 and bottomed at -$7.3 million in Q4 2025.
- Historically, Enterprise Value has averaged -$1.2 million across 5 years, with a median of -$76853.0 in 2023.
- On a YoY basis, Enterprise Value climbed as much as 99.66% in 2025 and fell as far as 6513695.54% in 2025.
- Citius Oncology's Enterprise Value stood at -$289175.0 in 2022, then soared by 88.68% to -$32746.0 in 2023, then surged by 99.66% to -$112.0 in 2024, then plunged by 6513695.54% to -$7.3 million in 2025, then jumped by 63.91% to -$2.6 million in 2026.
- Business Quant data shows CTOR's Enterprise Value at -$2.6 million in Q1 2026, -$7.3 million in Q4 2025, and -$3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | -164.00 Mn |
| 10 | Citius Oncology | 79.84 Mn | 79.84 Mn | 1.00 Mn | -16.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.63 Mn |
| Dec 31, 2025 | -7.30 Mn |
| Sep 30, 2025 | -3.92 Mn |
| Jun 30, 2025 | -112.00 |
| Mar 31, 2025 | -112.00 |
| Dec 31, 2024 | -112.00 |
| Sep 30, 2024 | -112.00 |
| Mar 31, 2024 | -33,330.00 |
| Dec 31, 2023 | -32,746.00 |
| Jun 30, 2023 | -370,095.00 |
| Mar 31, 2023 | -120,376.00 |
| Dec 31, 2022 | -289,175.00 |